Annette G Roberts, Ryan Kilpatrick, Lindsey D Diaz, Scott Benjamin, Athziry J Espinoza Santiago, Bubacarr Jallow, Madison F Monteith, Sarah Rumsey, Reese H Clark, Kanecia Zimmerman, Daniel K Benjamin, Rachel G Greenberg
{"title":"2005 至 2020 年新生儿重症监护病房加巴喷丁使用趋势。","authors":"Annette G Roberts, Ryan Kilpatrick, Lindsey D Diaz, Scott Benjamin, Athziry J Espinoza Santiago, Bubacarr Jallow, Madison F Monteith, Sarah Rumsey, Reese H Clark, Kanecia Zimmerman, Daniel K Benjamin, Rachel G Greenberg","doi":"10.1055/a-2451-9925","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong> This study aimed to analyze trends in gabapentin use in neonatal intensive care units (NICUs) and examine demographic characteristics, diagnoses, and concomitant medications associated with its use.</p><p><strong>Study design: </strong> Cohort study of 987,181 infants hospitalized in the NICU from 2005 to 2020.</p><p><strong>Results: </strong> Eighty-five infants (<0.01%) received gabapentin. From 2009 to 2020, there was a 1,055% relative increase in gabapentin use (<i>p</i> < 0.01). The median birth weight was 2,160 g (25th, 75th percentiles: 875, 3,080 g) in gabapentin-exposed infants compared with 2,498 g (1,890, 3,210 g) in unexposed infants (<i>p</i> < 0.001). Over half (55%) of infants receiving gabapentin were born prematurely, 54% (<i>n</i> = 45) had chronic lung disease, 46% (<i>n</i> = 39) had gastrostomy tubes, and 34% (<i>n</i> = 29) had drug withdrawal syndrome; 49% (<i>n</i> = 42) and 27% (<i>n</i> = 23) received opioids and benzodiazepines, respectively.</p><p><strong>Conclusion: </strong> Use of gabapentin was rare but increased over time despite limited research on its safety and efficacy in infants, illuminating the need for further studies.</p><p><strong>Key points: </strong>· Gabapentin safety in infants is not well understood.. · Gabapentin use increased despite limited safety research.. · Further studies on gabapentin use in infants are needed..</p>","PeriodicalId":7584,"journal":{"name":"American journal of perinatology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Trends in Gabapentin Use in Neonatal Intensive Care Units from 2005 to 2020.\",\"authors\":\"Annette G Roberts, Ryan Kilpatrick, Lindsey D Diaz, Scott Benjamin, Athziry J Espinoza Santiago, Bubacarr Jallow, Madison F Monteith, Sarah Rumsey, Reese H Clark, Kanecia Zimmerman, Daniel K Benjamin, Rachel G Greenberg\",\"doi\":\"10.1055/a-2451-9925\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong> This study aimed to analyze trends in gabapentin use in neonatal intensive care units (NICUs) and examine demographic characteristics, diagnoses, and concomitant medications associated with its use.</p><p><strong>Study design: </strong> Cohort study of 987,181 infants hospitalized in the NICU from 2005 to 2020.</p><p><strong>Results: </strong> Eighty-five infants (<0.01%) received gabapentin. From 2009 to 2020, there was a 1,055% relative increase in gabapentin use (<i>p</i> < 0.01). The median birth weight was 2,160 g (25th, 75th percentiles: 875, 3,080 g) in gabapentin-exposed infants compared with 2,498 g (1,890, 3,210 g) in unexposed infants (<i>p</i> < 0.001). Over half (55%) of infants receiving gabapentin were born prematurely, 54% (<i>n</i> = 45) had chronic lung disease, 46% (<i>n</i> = 39) had gastrostomy tubes, and 34% (<i>n</i> = 29) had drug withdrawal syndrome; 49% (<i>n</i> = 42) and 27% (<i>n</i> = 23) received opioids and benzodiazepines, respectively.</p><p><strong>Conclusion: </strong> Use of gabapentin was rare but increased over time despite limited research on its safety and efficacy in infants, illuminating the need for further studies.</p><p><strong>Key points: </strong>· Gabapentin safety in infants is not well understood.. · Gabapentin use increased despite limited safety research.. · Further studies on gabapentin use in infants are needed..</p>\",\"PeriodicalId\":7584,\"journal\":{\"name\":\"American journal of perinatology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-11-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of perinatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2451-9925\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of perinatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2451-9925","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Trends in Gabapentin Use in Neonatal Intensive Care Units from 2005 to 2020.
Objective: This study aimed to analyze trends in gabapentin use in neonatal intensive care units (NICUs) and examine demographic characteristics, diagnoses, and concomitant medications associated with its use.
Study design: Cohort study of 987,181 infants hospitalized in the NICU from 2005 to 2020.
Results: Eighty-five infants (<0.01%) received gabapentin. From 2009 to 2020, there was a 1,055% relative increase in gabapentin use (p < 0.01). The median birth weight was 2,160 g (25th, 75th percentiles: 875, 3,080 g) in gabapentin-exposed infants compared with 2,498 g (1,890, 3,210 g) in unexposed infants (p < 0.001). Over half (55%) of infants receiving gabapentin were born prematurely, 54% (n = 45) had chronic lung disease, 46% (n = 39) had gastrostomy tubes, and 34% (n = 29) had drug withdrawal syndrome; 49% (n = 42) and 27% (n = 23) received opioids and benzodiazepines, respectively.
Conclusion: Use of gabapentin was rare but increased over time despite limited research on its safety and efficacy in infants, illuminating the need for further studies.
Key points: · Gabapentin safety in infants is not well understood.. · Gabapentin use increased despite limited safety research.. · Further studies on gabapentin use in infants are needed..
期刊介绍：
The American Journal of Perinatology is an international, peer-reviewed, and indexed journal publishing 14 issues a year dealing with original research and topical reviews. It is the definitive forum for specialists in obstetrics, neonatology, perinatology, and maternal/fetal medicine, with emphasis on bridging the different fields.
The focus is primarily on clinical and translational research, clinical and technical advances in diagnosis, monitoring, and treatment as well as evidence-based reviews. Topics of interest include epidemiology, diagnosis, prevention, and management of maternal, fetal, and neonatal diseases. Manuscripts on new technology, NICU set-ups, and nursing topics are published to provide a broad survey of important issues in this field.
All articles undergo rigorous peer review, with web-based submission, expedited turn-around, and availability of electronic publication.
The American Journal of Perinatology is accompanied by AJP Reports - an Open Access journal for case reports in neonatology and maternal/fetal medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
